FDA approved<unk>  after preliminary results of the Reversal Effects of<unk>  on Active Dabigatran (RE-VERSE AD) study.
Idarucizumab
Tocilizumab
Sotrovimab
Obiltoxaximab
Sarilumab
Raxibacumab
Rituximab
Baricitinib